Table 1.
Patients characteristics
| Patients characteristics | Ongoing treatments | |||
| Age (y), mean (SD) | 68.7 (9.6) | Beta-blocker | 11 (15.3%) | |
| Age ≥ 75 y | 22 (30.6%) | Statin | 50 (69.4%) | |
| Male | 49 (68.1%) | PPI | 26 (36.1%) | |
| BMI ≥ 30 kg/m2 | 14 (20.0%) | ACE inhibitor/ARB | 42 (58.3%) | |
| Calcium channel blocker | 24 (33.3%) | |||
| Medical history | Laboratory test parameters | |||
| Hypertension | 48 (66.7%) | Clearance | 12 (16.7%) | |
| Hypercholesterolemia | 39 (54.2%) | (Cockroft-Gault) < 60 ml/min | ||
| Diabetes | 25 (34.7%) | Glycated hemoglobin ≥ 6% | 37 (52.9%) | |
| Current smokers | 18 (25%) | LDL Cholesterol ≥ 2.6 mmol/l | 41 (56.9%) | |
| Coronary artery disease | 7 (9.7%) | HDL Cholesterol ≤ 1 mmol/l | 24 (35.3%) | |
| Lower-limb arterial disease | 5 (6.9%) | Triglycerides ≥ 1.70 mmol/l | 27 (37.5%) | |
| Ischemic stroke or TIA | 14 (19.4%) | |||
| Characteristics of stroke/TIA | Radiological analysis | |||
| Type of event | Ischemic stroke | 63 (87.5%) | Simplified Fazekas score ≥ 2 | 29 (40.3%) |
| TIA | 9 (12.5%) | Presence of microbleed | 16 (22.2%) | |
| TOAST classification | I | 28 (38.9%) | ||
| III | 18 (25.0%) | |||
| V | 26 (36.1%) | |||
| NIHSS at admission | < 5 | 61 (84.7%) | ||
| ≥ 5 | 11 (15.3%) | |||
| mRS at discharge | < 3 | 63 (87.5%) | ||
| ≥ 3 | 9 (12.5%) |
ACE inhibitor: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; mRS: modified Rankin score; NIHSS: National Institutes of Health Stroke Score; NR patients: non-responder/low--responder/poor-responder patients; PPI: proton pump inhibitor; R patients: responder patients; SD: standard deviation; TIA: transient ischemic attack; TOAST: Trial of ORG 10172 in Acute Stroke Treatment.